Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Yutaka Kobayashi Insider Profile
4 Followers
Yutaka Kobayashi, Director at Medicinova, holds 60.00K shares in Medicinova (Ticker: MNOV). Most recently, Yutaka Kobayashi Bought $1,000 shares of Medicinova on May 16, 2017 for an estimated value of 5.60K.
Profitable Transactions
7 out of 9 Profitable Transactions
Average Return
+23.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Yutaka Kobayashi's holdings
Insider Roles
Director
Roles that Yutaka Kobayashi holds in companies
Most Profitable Insider Trade
The most profitable trade made by Yutaka Kobayashi
Yutaka Kobayashi's Trading History
List of latest transactions for each holding click on a transaction to see Yutaka Kobayashi's performance on stock
You May Also Like
Yutaka Kobayashi insider profile FAQ
What is the percentage of profitable transactions made by Yutaka Kobayashi?
The percentage of profitable transactions made by Yutaka Kobayashi is 78%.
What is the average return per transaction made by Yutaka Kobayashi?
The average return per transaction made by Yutaka Kobayashi is 23.10%.
What stocks does Yutaka Kobayashi hold?
Yutaka Kobayashi holds: MNOV stocks.
What was Yutaka Kobayashi’s latest transaction?
Yutaka Kobayashi latest transaction was an Informative Buy of $5.60K.
What was Yutaka Kobayashi's most profitable transaction?
Yutaka Kobayashi’s most profitable transaction was an Informative Buy of MNOV stock on May 15, 2017. The return on the trade was 88.60%.
What is Yutaka Kobayashi's role in Medicinova?
Yutaka Kobayashi's role in Medicinova is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.